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Long-Term Risk of Incident Type 2 Diabetes and
Measures of Overall and Regional Obesity: The EPIC-
InterAct Case-Cohort Study
The InterAct Consortium"*
Abstract
Background: Waist circumference (WC) is a simple and reliable measure of fat distribution that may add to the prediction of
type 2 diabetes (T2D), but previous studies have been too small to reliably quantify the relative and absolute risk of future
diabetes by WC at different levels of body mass index (BMI).
Methods and Findings: The prospective InterAct case-cohort study was conducted in 26 centres in eight European
countries and consists of 12,403 incident T2D cases and a stratified subcohort of 16,154 individuals from a total cohort of
340,234 participants with 3.99 million person-years of follow-up. We used Prentice-weighted Cox regression and random
effects meta-analysis methods to estimate hazard ratios for T2D. Kaplan-Meier estimates of the cumulative incidence of T2D
were calculated. BMI and WC were each independently associated with T2D, with WC being a stronger risk factor in women
than in men. Risk increased across groups defined by BMI and WC; compared to low normal weight individuals (BMI 18.5–
22.4 kg/m2) with a low WC (,94/80 cm in men/women), the hazard ratio of T2D was 22.0 (95% confidence interval 14.3;
33.8) in men and 31.8 (25.2; 40.2) in women with grade 2 obesity (BMI$35 kg/m2) and a high WC (.102/88 cm). Among the
large group of overweight individuals, WC measurement was highly informative and facilitated the identification of a
subgroup of overweight people with high WC whose 10-y T2D cumulative incidence (men, 70 per 1,000 person-years;
women, 44 per 1,000 person-years) was comparable to that of the obese group (50–103 per 1,000 person-years in men and
28–74 per 1,000 person-years in women).
Conclusions: WC is independently and strongly associated with T2D, particularly in women, and should be more widely
measured for risk stratification. If targeted measurement is necessary for reasons of resource scarcity, measuring WC in
overweight individuals may be an effective strategy, since it identifies a high-risk subgroup of individuals who could benefit
from individualised preventive action.
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Introduction
A higher body mass index (BMI) is a strong predictor of type 2
diabetes (T2D), with a linear increase in diabetes risk across the
whole spectrum of BMI [1]. Although diabetes risk is highest in
obese people with BMI$30 kg/m2, a great proportion of future
cases comes from the large population of overweight individuals
with a BMI between 25 and 30 kg/m2 [2]. Recent national figures
from the US and UK suggest that at least a third of the population
is now overweight and another third (24% UK) is obese [3,4], with
severe implications for the future burden of diabetes.
The Diabetes Prevention Program has shown that individual-
level lifestyle intervention can reduce the incidence of diabetes by
over 50% in high-risk individuals [5], an effect that persists for at
least 10 y [6]. Current clinical practice generally relies on
measurement of BMI to identify individuals at increased risk of
diabetes and other adiposity-related morbidity and mortality.
However, due to their high prevalence, it is financially and
logistically difficult to test and intervene on all overweight and
obese individuals.
BMI provides no information about body fat distribution, which
distinguishes the large amount of adipose tissue located subcuta-
neously from the smaller amount of intra-abdominal visceral fat,
known to predict the development of diabetes over and above BMI
[2,7,8]. Waist circumference (WC) is a simple measure that can be
used to diagnose abdominal obesity and identify individuals at
increased risk of T2D [9]. Information about WC is therefore
likely to be useful in distinguishing high- and low-risk individuals at
different levels of BMI, which is important for targeting those at
highest absolute risk for individually focused lifestyle intervention
to prevent T2D.
However, WC is not routinely assessed in clinical practice for a
range of reasons [10]. Although measurement is relatively simple
and cheap, it does require some training and standardisation, and
this has been cited as one reason for its limited use. Another
explanation is that practitioners do not appreciate the relevance of
the additional information that is derived from measuring WC
over and above BMI [10]. This may be because earlier studies
were generally too small to estimate T2D incidence rates at
different levels of BMI and WC with the precision required to
guide clinical decision making or inform policy recommendations.
In addition, men and women differ in the distribution of their
overall and abdominal body fat, but only large-scale studies
including men and women are adequately powered to investigate
sex differences in associations of BMI and WC with T2D with
confidence.
We use data from the European InterAct study, a case-cohort
study of 12,403 cases of incident T2D and a subcohort of 16,154
participants, conducted in 26 centres in eight European countries
to estimate the relative and cumulative risk of diabetes at different
levels of BMI and WC, separately in men and women.
Methods
Population
The design and methods of the InterAct case-cohort study have
previously been described in detail [11]. InterAct Consortium
partners identified individuals with T2D in European Prospective
Investigation into Cancer and Nutrition (EPIC) cohorts between
1991 and 2007 from eight of the ten countries participating in
EPIC (26 centres). Prevalent diabetes was identified on the basis
of baseline self-report of a history of diabetes, doctor-diagnosed
diabetes, diabetes drug use, or evidence of diabetes after baseline
with a date of diagnosis earlier than the baseline recruitment
date. All ascertained cases with any evidence of diabetes at
baseline were excluded. Ascertainment of incident T2D involved
a review of the existing EPIC datasets at each centre using
multiple sources of evidence including self-report, linkage to
primary-care registers, secondary-care registers, medication use
(drug registers), hospital admissions and mortality data. Informa-
tion from any follow-up visit or external evidence with a date
later than the baseline visit was used. To increase the specificity of
the case definition, we sought further evidence for all cases with
information on incident T2D from fewer than two independent
sources at a minimum, which included individual medical records
review in some centres. Cases in Denmark and Sweden were not
ascertained by self-report, but identified via local and national
diabetes and pharmaceutical registers, and hence all ascertained
cases were considered to be verified. Follow-up was censored at
the date of diagnosis, 31 December 2007, or the date of death,
whichever occurred first. A total of 340,234 participants of
European descent were followed up for 3.99 million person-years
(mean [range] of follow-up 11.7 [0–17.5] y), during which 12,403
verified incident cases of T2D were identified [11]. Individuals
without stored blood (n = 109,625) or without reported diabetes
status (n = 5,821) were excluded. A centre-stratified, random
subcohort of 16,835 individuals was selected; after exclusion of
548 individuals with prevalent diabetes and 133 with unknown
diabetes status, the subcohort included 16,154 individuals for
analysis. Due to the random selection, this subcohort also
included a random set of 778 individuals who had developed
incident T2D during follow-up. Participants in the random
subcohort were similar to all EPIC participants eligible for
inclusion in InterAct [11]. InterAct cases were followed-up for a
mean (standard deviation [SD]) of 6.9 (3.3) y; 49.8% were men.
The overall incidence in InterAct was 3.8 per 1,000 person-years
of follow-up; country-specific rates are included in the InterAct
cohort description [11].
Measurements
Weight and height were measured with participants not wearing
shoes and in light clothing or underwear in the majority of centres,
as described previously [12]. WC was measured either at the
narrowest circumference of the torso or at the midpoint between
the lower ribs and the iliac crest. Hip circumference was measured
horizontally at the level of the largest lateral extension of the hips
or over the buttocks. For a subset of the Oxford (UK) participants
(n = 363), only self-reported waist and hip circumferences were
available. Each participant’s body weight and waist and hip
circumferences were corrected for the clothing worn during
measurement in order to reduce heterogeneity due to protocol
differences among centres [13]. Correction included adjustment
for self-reporting in Oxford participants using a prediction
equation based on a comparison of self-reported and measured
data in a sample of 5,000 of the Oxford general population
[12,14]. BMI was calculated as weight (in kilograms)/height (in
metres) squared. Waist-hip ratio was calculated and expressed as a
percentage. Measures of waist or hip circumference were not
performed at the centre in Umea, Sweden (n = 1,845), and were
missing in an additional 173 and 193 InterAct participants for
waist and hip, respectively.
As part of EPIC, standardised information on education and
smoking status was collected by questionnaire at baseline [15].
Physical activity was assessed using a brief questionnaire covering
occupation and recreational activity [16,17].
Overall and Regional Obesity and Incident Diabetes
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Statistical Analysis
Characteristics of the subcohort are described using summary
statistics (means, SDs, frequencies, and percentages) separately for
men and women. Associations between anthropometric variables
and the hazard of diabetes were estimated using Prentice-weighted
Cox regression models with age as the underlying time scale,
separately within each centre and then combined across centres
using random effects meta-analysis [11]. We calculated internally
derived sex-specific standardised scores based on means and SDs
within the subcohort for each anthropometric measure. We
divided study participants into normal weight (BMI 18.5–24.9 kg/
m2), overweight (25.0–29.9 kg/m2), or obese ($30 kg/m2) based
on current World Health Organization criteria [18], and used sex-
specific cut-offs to define WC as normal (,94 cm [,34.6 inches]
in men and ,80 cm [31.5 inches] in women), moderately
increased (94–102 cm [34.6–40 inches] in men and 80–88 cm
[31.5–35 inches] in women), or large ($102 cm [$40 inches] in
men and $88 cm [$35 inches] in women) [18,19]. We excluded
189 participants (172 subcohort members and 17 cases from
outside the subcohort) who were underweight (BMI,18.5 kg/m2)
from all analyses. Using standardised, continuous measures and
categorical BMI and WC variables, we compared the effect
estimates for associations between each anthropometric measure
and the risk of diabetes, separately for men and women, before
and after adjustments. Adjustments included other anthropometric
measures, smoking, education, and physical activity, as specified
for all models in the corresponding tables.
Where heterogeneity was observed in the effect estimates
between centres, meta-regression was used to explore the extent to
which the average age, BMI, or WC in each centre explained the
heterogeneity. To assess whether the effect estimate of WC
differed between men and women, a sex by WC (continuous
variable) interaction term was included in the centre-specific
Prentice-weighted Cox regression models, and the estimated
interaction coefficients were then combined across centres using
random effects meta-analysis. A similar analysis was performed to
assess the evidence for a BMI group by WC group interaction
using standard, clinical cut-offs.
To investigate the hazard ratio (HR) of diabetes by BMI and
WC levels in more detail, we further subdivided study participants
who had measures of BMI and WC into six BMI groups (18.5–
22.4, 22.5–24.9, 25–27.4, 27.5–29.9, 30.0–34.9, and $35 kg/m2).
Analyses were performed using Stata version 12 (StataCorp)
Within Stata, the –st- suite of commands for performing survival
analysis was used.
To estimate the cumulative incidence of diabetes we performed
bootstrap sampling using the Stata bsample command to recreate
the full cohort by resampling with replacement from the
subcohort, according to the BMI and WC distributions within
the subcohort. This made it possible to estimate absolute
cumulative incidences (one minus the Kaplan-Meier estimate of
the survivor function) for normal, increased, and large WC groups
separately within the groups of normal, overweight, and obese
men and women.
Results
Characteristics of men and women who were part of the
subcohort are shown in Tables 1 and 2. A total of 50.0% of men
and 33.8% of women were overweight, and 16.4% of men and
15.8% of women were obese. Overweight or obese men and
women were shorter and had larger WCs and waist-hip ratios
than participants with normal baseline BMI (all p,0.001).
Overweight or obese men and women were more likely to be
physically inactive and to be educated at primary school level or
less (all p,0.001). While obese men were less likely to be never
smokers and more likely to be former smokers, the opposite was
observed in obese women, who were more likely to be never
smokers and less likely to be former or current smokers (all
p,0.001).
Contributions of BMI and Waist Circumference to the
Hazard of T2D
Significant, positive associations between both BMI and WC
and the hazard of T2D were observed across all countries and
centres in men and women (Figures 1–4). The pooled effect
estimate (HR) for a 1 SD increase in BMI (SD 3.6 kg/m2 in men,
4.4 kg/m2 in women) was 1.93 (95% confidence interval 1.81;
2.06) in men and 2.07 (1.94; 2.21) in women; corresponding
estimates for WC (SD 10.0 cm in men, 11.2 cm in women) were
1.95 (1.83; 2.08) in men and 2.43 (2.23; 2.64) in women (Figures 1–
4; Table 3). There was heterogeneity between centres in the HRs
for both BMI and WC (Figures 1–4), which was not explained by
differences in the average age of participants in the different
centres. A higher average WC was associated with a lower HR per
1 SD increase in BMI; inclusion of average WC in a meta-
regression model reduced the I2 values from 48% to 0% in men
and from 59% to 52% in women. However, average BMI did not
explain the heterogeneity in the WC to T2D associations in either
men or women. There was no significant interaction between BMI
and WC in either men (interaction parameter estimate 0.97 [0.85;
1.11], p = 0.66) or women (interaction parameter estimate 1.10
[0.99; 1.22], p = 0.073).
Differences in Associations between Men and Women
The stronger association between WC and incident T2D in
women, compared to men, became more apparent in models
mutually adjusting for WC and BMI (Table 3). While the
independent contributions of a sex-specific SD increase in WC
and BMI to the hazard of diabetes were of similar magnitude in
men (1.39 [1.19; 1.63] for WC and 1.49 [1.27; 1.73] for BMI), the
increased hazard of diabetes conveyed by a larger WC as opposed
to higher BMI was much larger in women (2.14 [1.87; 2.45] for
WC and 1.15 [1.02; 1.30] for BMI). A disproportionately
increased HR of diabetes in women (HR 11.3 [9.15; 13.9])
compared to men (HR 5.36 [4.38; 6.54]; Table 3) was also seen
using sex-specific cut-offs clinically used to identify individuals with
central adiposity and excess visceral fat (.102 cm [40 inches] in
men and .88 cm [35 inches] in women). Consistently greater
HRs were observed in women across all study centres (Figure S1),
with sex ratios (HRwomen/HRmen) ranging from 1.03 to 3.31 and a
pooled sex ratio of 1.69 (1.42; 2.02). The higher hazard associated
with greater WC in women was not explained by confounding by
BMI, since the BMI adjusted pooled sex ratio was 1.60 (1.34;
1.90).
Hazard Ratio of Diabetes at Different Levels of Waist
Circumference and BMI
BMI and WC are highly positively correlated (r = 0.85 in men
and 0.87 in women in the subcohort). Therefore, too few men and
women with a BMI of 18.5–22.4 kg/m2 had a WC greater than or
equal to 94/80 cm (n = 130) and too few men with a BMI of 22.5–
24.9 kg/m2 had a WC greater than or equal to 102 cm (n = 13) to
contribute to stratified analyses (Tables 4 and 5). The same was
true for participants with a BMI of 30–34.9 kg/m2 and a WC
lower than 94/80 cm (n = 49), or those with a BMI greater or
equal to 35 kg/m2 and a WC lower than 102/88 cm (n = 14).
Overall and Regional Obesity and Incident Diabetes
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Figure 1. Hazard ratios for type 2 diabetes per 1 SD increase in BMI (SD=3.6 kg/m2) in men. Heterogeneity between centres: I2 = 48%
(p = 0.012). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are
combined using random effects meta-analysis.
doi:10.1371/journal.pmed.1001230.g001
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Compared to those with a BMI of 18.5–22.4 kg/m2 and normal
WC, the HR of diabetes was successively higher at greater levels of
BMI and WC, ranging from 1.53 (1.20; 1.95) in men and 1.71
(1.39; 2.09) in women with normal weight at BMI 22.5–24.9 kg/
m2 and a normal WC, to 22.0 (14.3; 33.8) in men and 31.8 (25.2;
40.2) in women with a BMI greater or equal to 35 kg/m2 and a
high WC. The HR of diabetes was generally higher (or similar)
when comparing people in a lower BMI but higher WC group to
those in the BMI group above with a smaller WC, an effect that
was particularly pronounced in women. For example, in
overweight women, the HR in those with a BMI of 25.0–
27.4 kg/m2 and a large WC ($88 cm) was 10.3 (8.00; 13.3), but
was 5.82 (4.64; 7.31) in those with a BMI of 27.5–29.9 kg/m2 and
a moderately increased WC ($80–87.9 cm).
Cumulative 10-y Incidence of Developing Diabetes
Figures 5 and 6 show the cumulative incidence of T2D over
10 y of follow-up for different groups of BMI and WC, separately
in men and women. Tables S1 and S2 additionally include
cumulative incidences for three different follow-up times (5, 10,
15 y) together with 95% confidence intervals, numbers of events,
and person-years of follow-up. The cumulative 10-y incidences
estimated in normal weight participants (BMI 18.5–24.9 kg/m2)
were 1.2%, 2.8%, and 2.2% in men with a normal (,94 cm),
moderately increased ($94–101.9 cm), and large ($102 cm) WC;
the corresponding figures for women with a normal (,80 cm),
moderately increased ($80–87.9 cm), and large ($88 cm) WC
were 0.59%, 1.5%, and 2.0%. In overweight individuals, WC
distinguished those with incidence rates comparable to normal
weight from those with rates equivalent to obese individuals.
Cumulative 10–y incidences for men with normal, moderately
increased, and large WC were 2.3%, 3.9%, and 7.0% in
overweight men and 5.0%, 4.9%, and 10.3% in obese men.
Corresponding figures were 1.1%, 2.0%, and 4.4% in overweight
women and 2.8%, 2.7%, and 7.4% in obese women, respectively.
Discussion
Results based on 12,403 incident cases of T2D identified in 26
centres in eight European countries as part of the InterAct case-
cohort study show independent, significant contributions of both
BMI and WC to the risk of T2D. We found greater HRs for WC
in women, compared to men, in analyses of standardised,
continuous measures as well as using recommended clinical
thresholds for abdominal obesity. In terms of absolute risk, 7% of
men and 4.4% of women who were overweight and had a large
WC at baseline developed diabetes over a 10-y period, placing
them at an absolute risk equivalent to or higher than that of obese
participants.
Clinical Implications
In addition to obese and severely obese individuals at high risk
of diabetes, more than a third of the population in the US and UK
is overweight [3,4]. These individuals’ risk of T2D is much less
well defined, despite its potentially greater contribution to the
absolute burden of diabetes and related complications. We show
that assessment of WC identifies those at high risk of T2D among
the large group of individuals who are overweight. Individual
lifestyle interventions can reduce diabetes risk [5], but are not
feasible in everyone who is overweight or obese. Current clinical
practice relies on BMI to identify overweight and obese individuals
at increased risk of diabetes and other adiposity-related morbidity
and mortality. Although measurement of WC is often recom-
mended in clinical guidelines, it is rarely actually performed. In a
survey of practice nurses in the UK, 96% reported measuring BMI
in a typical week, but only 12% measured WC [20]. Recommen-
dations to measure WC on everyone are unlikely to be successful
since time pressures are cited as one of the explanations for the
implementation gap between recommendations and actual clinical
practice. Thus risk prediction models for T2D that assume
universal measurement are unlikely to be helpful. As an alternative
strategy, practice could focus measurement of WC on subgroups
in whom the additional information is likely to make a difference
to clinical decision making. Our results suggest that current clinical
recommendations should consider the introduction of WC
measurement amongst all overweight men and women to identify
high-risk individuals for early lifestyle intervention. Normal weight
men and women were at sufficiently low absolute risk that
measurement of WC would not change their risk categorisation.
People in the obese group should already be targeted for
individualised lifestyle intervention programmes, and measure-
ment of WC would not alter this recommendation. This
observation, of course, does not imply that WC is an unimportant
aetiological risk factor in normal weight and obese individuals, but
rather that its measurement in these groups does not have an
impact on clinical decision making.
Public Health Implications
The frequency of diabetes in combination with its severe long-
term complications through organ damage and dysfunction,
particularly of the cardiovascular system, create a major public
health problem and serious burden on health care systems.
Obesity is the strongest risk factor for T2D, and World Health
Organization projections estimate that by 2015 approximately 2.3
billion adults will be overweight, more than 700 million will be
obese, and diabetes deaths will increase by more than 50%
worldwide during this time [21]. Prevention strategies for T2D
require a balance of investment between population-level inter-
ventions aimed at shifting the whole distribution of key risk factors
and individually focused lifestyle interventions targeted at high-risk
individuals. Our results clearly show the value that measurement
of WC may have in identifying which people among the large
population of overweight individuals are at highest risk of diabetes.
Comparison with Previous Studies
Previous literature-based reviews have investigated associations
between BMI, WC, or other measures of abdominal obesity and
incident diabetes [7,8,22] and reported similar associations, with
risks being approximately twice as large per 1 SD difference in the
different obesity measures. Results from the EPIC Potsdam cohort
including 1,008 incident T2D cases suggested that the relative risk
of T2D associated with WC is smaller in obese than in normal and
overweight men and women [23]. We found no evidence for a
significant interaction between BMI and WC in men or women in
the InterAct study, which includes incident cases from the EPIC
Potsdam cohort. Individual studies and meta-analyses investigat-
ing the separate and joint contributions of measures of overall and
central adiposity have often focused on their respective aetiological
relevance [2,7,8,23]. However, it is difficult to draw inference
about the specific role of central and abdominal obesity for
diabetes development from epidemiological analyses mutually
adjusting for BMI and WC given the strong correlation between
these measures and differences in their respective measurement
errors [9].
Although associations of BMI and WC with T2D incidence did
not differ substantially between countries, and effect estimates of
BMI and WC appeared largely consistent, we observed significant
heterogeneity in our meta-analyses, with I2 values of 48% and
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Figure 2. Hazard ratios for type 2 diabetes per 1 SD increase in BMI (SD=4.4 kg/m2) in women. Heterogeneity between centres: I2 = 59%
(p = 0.012). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are
combined using random effects meta-analysis.
doi:10.1371/journal.pmed.1001230.g002
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Figure 3. Hazard ratios for type 2 diabetes per 1 SD increase in WC (SD=10.0 cm) in men. Heterogeneity between centres: I2 = 31%
(p = 0.11). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are
combined using random effects meta-analysis.
doi:10.1371/journal.pmed.1001230.g003
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Figure 4. Hazard ratios for type 2 diabetes per 1 SD increase in WC (SD=11.2 cm) in women. Heterogeneity between centres: I2 = 69%
(p,0.001). HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are
combined using random effects meta-analysis.
doi:10.1371/journal.pmed.1001230.g004
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Table 3. Anthropometric measures and incident type 2 diabetes.
Measure Men Women
SD HR (95% CI) SD HR (95% CI)
BMI
18.5–24.9 kg/m2 1 1
25.0–29.9 kg/m2 2.84 (2.33, 3.45) 3.81 (3.18, 4.58)
$30.0 kg/m2 7.58 (6.00, 9.57) 11.6 (9.20, 14.5)
WC
,94/80 cm 1 1
$94–101.9/80–87.9 cm 2.40 (2.01, 2.88) 3.02 (2.61, 3.48)
$102/88 cm 5.36 (4.38, 6.54) 11.3 (9.15, 13.9)
Per 1 SD increase in BMI 3.6 4.4
Unadjusted 1.93 (1.81, 2.06) 2.07 (1.94, 2.21)
Adjusted for WC 1.49 (1.27, 1.73) 1.15 (1.02, 1.30)
Adjusted for WC, physical activity, smoking, and education 1.58 (1.36, 1.83) 1.16 (1.01, 1.34)
Per 1 SD increase in WC 10.0 11.2
Unadjusted 1.95 (1.83, 2.08) 2.43 (2.23, 2.64)
Adjusted for height 2.03 (1.88, 2.20) 2.46 (2.27, 2.68)
Adjusted for BMI 1.39 (1.19, 1.63) 2.14 (1.87, 2.45)
Adjusted for BMI, physical activity, smoking, and education 1.37 (1.19, 1.58) 2.25 (1.90, 2.66)
Per 1 SD increase in waist-hip ratio 6.3 6.5
Unadjusted 1.81 (1.61, 2.03) 2.15 (1.93, 2.40)
Adjusted for BMI 1.38 (1.25, 1.52) 1.71 (1.57, 1.86)
Adjusted for BMI, physical activity, smoking, and education 1.33 (1.21, 1.47) 1.75 (1.58, 1.93)
HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Centre-specific estimates are combined using random
effects meta-analysis.
doi:10.1371/journal.pmed.1001230.t003
Table 4. Combinations of BMI and waist circumference groups and type 2 diabetes in men.
Weight Category BMI (kg/m2) WC (centimetres)
,94 $94–101.9 $102
Underweight ,18.5
20/3 0/0 0/0
Normal 18.5–22.4 1 (Reference group)
625/109 8/3 0/0
22.5–24.9 1.53 (1.20, 1.95) 3.00 (1.84, 4.89)
1,412/375 308/120 13/5
Overweight 25.0–27.4 2.76 (1.74, 4.37) 4.49 (2.74, 7.36) 5.67 (2.84, 11.3)
1,203/439 1,328/634 248/137
27.5–29.9 3.77 (2.53, 5.61) 6.05 (3.87, 9.45) 8.91 (5.69, 13.9)
233/97 1,335/749 1,044/707
Obese 30.0–34.9 7.48 (4.55, 12.3) 13.3 (8.32, 21.1)
27/16 314/183 2,111/1,550
$35.0 22.0 (14.3, 33.8)
0/0 5/4 557/470
HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Country-specific estimates are combined using random
effects meta-analysis. Sample size and case number stated per cell.
doi:10.1371/journal.pmed.1001230.t004
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Table 5. Combinations of BMI and waist circumference groups and type 2 diabetes in women.
Weight Category BMI (kg/m2) WC (centimetres)
,80 $80–87.9 $88
Underweight ,18.5
139/13 0/0 1/1
Normal 18.5–22.4 1 (Reference group)
2,325/257 108/28 14/4
22.5–24.9 1.71 (1.39, 2.09) 3.47 (2.70, 4.45) 5.55 (3.44, 8.95)
2,100/344 798/228 115/40
Overweight 25.0–27.4 2.47 (1.93, 3.18) 5.10 (4.16, 6.25) 10.3 (8.00, 13.3)
765/165 1,430/497 659/338
27.5–29.9 4.90 (3.12, 7.69) 5.82 (4.64, 7.31) 13.7 (10.1, 18.6)
120/41 867/333 1,375/778
Obese 30.0–34.9 6.10 (4.29, 8.66) 18.6 (14.6, 23.8)
22/9 229/94 2,512/1,646
$35.0 31.8 (25.2, 40.2)
0/0 9/4 1,271/980
HRs estimated from modified Cox regression with age as the underlying time scale, using Prentice weights. Country-specific estimates are combined using random
effects meta-analysis. Sample size and case number stated per cell.
doi:10.1371/journal.pmed.1001230.t005
Figure 5. Cumulative incidence of type 2 diabetes over 10 y by BMI and waist circumference groups in men. Red line, WC,94 cm; blue
line, WC$94–101.9 cm; black line, WC$102 cm.
doi:10.1371/journal.pmed.1001230.g005
Overall and Regional Obesity and Incident Diabetes
PLoS Medicine | www.plosmedicine.org 12 June 2012 | Volume 9 | Issue 6 | e1001230
31% for BMI and WC in men and 59% and 69% in women.
Meta-regression analyses showed that this heterogeneity was not
explained by differences in the average age of participants from
the different countries. In contrast, centres with higher average
WCs tended to have lower effect estimates of BMI, and inclusion
of average WC in meta-regression analyses reduced the I2 in men
from 48% to 0% and in women from 59% to 52%. Average BMI
did not explain heterogeneity in the association between WC and
T2D in men and women.
Sex Differences
We observed a stronger effect estimate for excess abdominal fat
in women compared to men using different analytical strategies.
This was not due to sex differences in the correlation between WC
and BMI, which was similar in both sexes (0.86 in men and 0.87 in
women in the subcohort). Also, sex differences in the association
between WC and T2D were not explained by height, which was
shown to only have a very marginal influence on the association.
Previous work has highlighted the value of WC as an index of
abdominal fat accumulation when it is interpreted in the context of
overall levels of adiposity [24,25]. In this study, sex differences in
the association between WC and T2D were particularly
pronounced after adjusting for BMI. This suggests that WC may
be a better measure of abdominal fat and diabetes risk in women
once differences in overall body size are accounted for, potentially
because of a greater contribution of subcutaneous fat to women’s
WC levels, compared to men.
These results demonstrate that women at greater relative risk of
T2D are identified when using recommended, sex-specific WC
cut-offs and suggest that cut-offs need to be reviewed if the aim is
to target comparable levels of relative risk in men and women.
However, if the aim is to target groups based on absolute risk, then
the observation that absolute levels of T2D risk are lower in
women at any level of WC compared to men is more important.
Strengths and Weaknesses
This is the largest study of incident diabetes to date to
investigate the separate and joint contributions of BMI and WC.
Advantages of our study include its power, prospective design,
and international, multicentre population. Inclusion of over
12,000 incident cases allows investigation of T2D risk for
different combinations of BMI and WC cut-offs with greater
precision. The prospective design of the InterAct case-cohort
study minimises systematic error introduced by recall or
treatment bias that cross-sectional and case-control studies are
subject to. Investigation on a Europe-wide scale increases the
generalisability of our findings. However, while the possibility of
examining anthropometric effects across the eight European
countries can help to understand factors contributing to any
potential heterogeneity, results from our European descent
InterAct participants do not allow inferences about BMI- and
WC-associated relative or absolute risks of T2D in other ethnic
groups with potentially different body composition and T2D
incidence. Methods for case ascertainment and verification in
Figure 6. Cumulative incidence of type 2 diabetes over 10 y by BMI and waist circumference groups in women. Red line, WC,80 cm;
blue line, WC$80–87.9 cm; black line, WC$88 cm.
doi:10.1371/journal.pmed.1001230.g006
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InterAct are largely based on a clinical diagnosis of T2D.
Estimates of the cumulative incidence in InterAct are therefore
an underestimation, potentially differential with regard to obesity
levels, as rates are expected to be higher if undiagnosed,
asymptomatic diabetes cases were also considered. While our
large-scale study had standardised measures of anthropometry
available for all except 363 Oxford participants, some differences
existed between centres in terms of the WC measurement site or
the clothes worn during measurement. Assuming that any
misclassification was non-differential with regard to case status,
this may have led to an attenuation of the observed associations
for WC, highlighting the importance of appropriately designed
and powered studies with standardised measures of WC to
address its relative importance for the risk of diabetes and other
outcomes.
Conclusion
WC is independently and strongly associated with T2D,
particularly in women, and should be more widely measured. If
targeted measurement is necessary for reasons of resource scarcity,
measuring WC in overweight individuals may be an effective
strategy since it identifies a high-risk subgroup of individuals who
could benefit from individualised preventive action.
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Editors’ Summary
Background. Worldwide, more than 350 million people
have diabetes, and this number is increasing rapidly.
Diabetes is characterized by dangerous levels of glucose
(sugar) in the blood. Blood sugar levels are usually controlled
by insulin, a hormone that the pancreas releases after meals
(digestion of food produces glucose). In people with type 2
diabetes (the commonest form of diabetes), blood sugar
control fails because the fat and muscle cells that normally
respond to insulin by removing sugar from the blood
become insulin resistant. Type 2 diabetes can be controlled
with diet and exercise, and with drugs that help the pancreas
make more insulin or that make cells more sensitive to
insulin. The long-term complications of diabetes, which
include an increased risk of heart disease and stroke, reduce
the life expectancy of people with diabetes by about 10
years compared to people without diabetes.
WhyWas This Study Done? A high body mass index (BMI,
a measure of body fat calculated by dividing a person’s
weight in kilograms by their height in meters squared) is a
strong predictor of type 2 diabetes. Although the risk of
diabetes is greatest in obese people (who have a BMI of
greater than 30 kg/m2), many of the people who develop
diabetes are overweight—they have a BMI of 25–30 kg/m2.
Healthy eating and exercise reduce the incidence of diabetes
in high-risk individuals, but it is difficult and expensive to
provide all overweight and obese people with individual
lifestyle advice. Ideally, a way is needed to distinguish
between people with high and low risk of developing
diabetes at different levels of BMI. Waist circumference is a
measure of fat distribution that has the potential to quantify
diabetes risk among people with different BMIs because it
estimates the amount of fat around the abdominal organs,
which also predicts diabetes development. In this case-
cohort study, the researchers use data from the InterAct
study (which is investigating how genetics and lifestyle
interact to affect diabetes risk) to estimate the long-term risk
of type 2 diabetes associated with BMI and waist circumfer-
ence. A case-cohort study measures exposure to potential
risk factors in a group (cohort) of people and compares the
occurrence of these risk factors in people who later develop
the disease and in a randomly chosen subcohort.
What Did the Researchers Do and Find? The researchers
estimated the association of BMI and waist circumference
with type 2 diabetes from baseline measurements of the
weight, height, and waist circumference of 12,403 people
who subsequently developed type 2 diabetes and a
subcohort of 16,154 participants enrolled in the European
Prospective Investigation into Cancer and Nutrition (EPIC).
Both risk factors were independently associated with type 2
diabetes risk, but waist circumference was a stronger risk
factor in women than in men. Obese men (BMI greater than
35 kg/m2) with a high waist circumference (greater than
102 cm) were 22 times more likely to develop diabetes than
men with a low normal weight (BMI 18.5–22.4 kg/m2) and a
low waist circumference (less than 94 cm); obese women
with a waist circumference of more than 88 cm were 31.8
times more likely to develop type 2 diabetes than women
with a low normal weight and waist circumference (less than
80 cm). Importantly, among overweight people, waist
circumference measurements identified a subgroup of
overweight people (those with a high waist circumference)
whose 10-year cumulative incidence of type 2 diabetes was
similar to that of obese people.
What Do These Findings Mean? These findings indicate
that, among people of European descent, waist circumfer-
ence is independently and strongly associated with type 2
diabetes, particularly among women. Additional studies are
needed to confirm this association in other ethnic groups.
Targeted measurement of waist circumference in overweight
individuals (who now account for a third of the US and UK
adult population) could be an effective strategy for the
prevention of diabetes because it would allow the identifi-
cation of a high-risk subgroup of people who might benefit
from individualized lifestyle advice.
Additional Information. Please access these web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001230.
N The US National Diabetes Information Clearinghouse
provides information about diabetes for patients, health
care professionals, and the general public, including
detailed information on diabetes prevention (in English
and Spanish)
N The US Centers for Disease Control and Prevention
provides information on all aspects of overweight and
obesity (including some information in Spanish)
N The UK National Health Service Choices website provides
information for patients and carers about type 2 diabetes,
about the prevention of type 2 diabetes, and about
obesity; it also includes people’s stories about diabetes
and about obesity
N The charity Diabetes UK also provides detailed information
for patients and carers, including information on healthy
lifestyles for people with diabetes, and has a further
selection of stories from people with diabetes; the charity
Healthtalkonline has interviews with people about their
experiences of diabetes
N More information on the InterAct study is available
N MedlinePlus provides links to further resources and advice
about diabetes and diabetes prevention and about obesity
(in English and Spanish)
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